Lancet:abrocitinib单药用于中重度特应性皮炎的治疗

2020-07-25 MedSci原创 MedSci原创

对于青少年和成人中度至重度特应性皮炎患者,每日一次口服abrocitinib是有效且耐受性良好的

Abrocitinib是一种口服选择性Janus激酶1抑制剂,在2b期试验中对成人中重度特应性皮炎有效且耐受性良好。近日研究人员评估了Abrocitinib单药治疗青少年和成人中重度特应性皮炎的有效性和安全性。
 
JADE MONO-1为III期临床研究,12岁以上,患有中度至重度特应性皮肤炎患者参与,随机接受100 mg、200mg的abrocitinib或安慰剂,每日一次,为期12周。共同终点是获得整体评估反应的患者的比例(定义为评分为0[清除]或1[几乎清除],且比基线有≥2级改善)以及在EASI-75评分比基线至少提高75%的患者的比例。
 
387名患者参与研究,156名患者接受100mg的abrocitinib治疗,154名患者接受200mg的abrocitinib治疗,77名患者接受安慰剂。第12周,100mg abrocitinib组达到总体评估反应的患者比例显著高于安慰剂组(156名患者中有37名vs 76名患者中的6名),abrocitinib 200 mg组达到总体评估反应的患者比例显著高于安慰剂组(153例患者中67例vs76例患者中的6例)。与安慰剂组相比,第12周,abrocitinib 100 mg组(62/156 vs 9/76)和abrocitinib 200 mg组(96/153  vs 9/76)获得EASI-75应答的患者比例显著高于安慰剂组。abrocitinib 100mg组156例患者中有108例(69%)出现不良事件,abrocitinib 200mg组154例患者中有120例(78%)出现不良事件,安慰剂组77例患者中有44例(57%)出现不良事件。abrocitinib 100mg组156例患者中有5例(3%)出现严重不良事件,abrocitinib 200mg组154例患者中有5例(3%)出现严重不良事件,安慰剂组77例患者中有3例(4%)出现严重不良事件。无治疗相关死亡报告。
 
对于青少年和成人中度至重度特应性皮炎患者,每日一次口服abrocitinib是有效且耐受性良好的。
 
原始出处:
 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830755, encodeId=590d1830e55fe, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Feb 21 09:51:29 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738582, encodeId=f7fe1e38582cd, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sun Aug 16 10:51:29 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813695, encodeId=2c9881369509, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:53:06 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977024, encodeId=b68219e7024dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Tue Jun 01 16:51:29 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033899, encodeId=82dc103389958, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Jul 25 12:51:29 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804484, encodeId=b72b80448487, content=<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>这个领域新药越来越多, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103769, encryptionId=f12a103e6970, topicName=特异性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jul 25 10:20:41 CST 2020, time=2020-07-25, status=1, ipAttribution=)]
    2021-02-21 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830755, encodeId=590d1830e55fe, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Feb 21 09:51:29 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738582, encodeId=f7fe1e38582cd, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sun Aug 16 10:51:29 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813695, encodeId=2c9881369509, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:53:06 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977024, encodeId=b68219e7024dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Tue Jun 01 16:51:29 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033899, encodeId=82dc103389958, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Jul 25 12:51:29 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804484, encodeId=b72b80448487, content=<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>这个领域新药越来越多, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103769, encryptionId=f12a103e6970, topicName=特异性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jul 25 10:20:41 CST 2020, time=2020-07-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1830755, encodeId=590d1830e55fe, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Feb 21 09:51:29 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738582, encodeId=f7fe1e38582cd, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sun Aug 16 10:51:29 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813695, encodeId=2c9881369509, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:53:06 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977024, encodeId=b68219e7024dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Tue Jun 01 16:51:29 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033899, encodeId=82dc103389958, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Jul 25 12:51:29 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804484, encodeId=b72b80448487, content=<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>这个领域新药越来越多, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103769, encryptionId=f12a103e6970, topicName=特异性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jul 25 10:20:41 CST 2020, time=2020-07-25, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1830755, encodeId=590d1830e55fe, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Feb 21 09:51:29 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738582, encodeId=f7fe1e38582cd, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sun Aug 16 10:51:29 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813695, encodeId=2c9881369509, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:53:06 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977024, encodeId=b68219e7024dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Tue Jun 01 16:51:29 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033899, encodeId=82dc103389958, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Jul 25 12:51:29 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804484, encodeId=b72b80448487, content=<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>这个领域新药越来越多, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103769, encryptionId=f12a103e6970, topicName=特异性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jul 25 10:20:41 CST 2020, time=2020-07-25, status=1, ipAttribution=)]
    2021-06-01 linlin2312
  5. [GetPortalCommentsPageByObjectIdResponse(id=1830755, encodeId=590d1830e55fe, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Feb 21 09:51:29 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738582, encodeId=f7fe1e38582cd, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sun Aug 16 10:51:29 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813695, encodeId=2c9881369509, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:53:06 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977024, encodeId=b68219e7024dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Tue Jun 01 16:51:29 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033899, encodeId=82dc103389958, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Jul 25 12:51:29 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804484, encodeId=b72b80448487, content=<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>这个领域新药越来越多, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103769, encryptionId=f12a103e6970, topicName=特异性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jul 25 10:20:41 CST 2020, time=2020-07-25, status=1, ipAttribution=)]
    2020-07-25 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1830755, encodeId=590d1830e55fe, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Feb 21 09:51:29 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738582, encodeId=f7fe1e38582cd, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sun Aug 16 10:51:29 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813695, encodeId=2c9881369509, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:53:06 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977024, encodeId=b68219e7024dc, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Tue Jun 01 16:51:29 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033899, encodeId=82dc103389958, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Jul 25 12:51:29 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804484, encodeId=b72b80448487, content=<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>这个领域新药越来越多, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103769, encryptionId=f12a103e6970, topicName=特异性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jul 25 10:20:41 CST 2020, time=2020-07-25, status=1, ipAttribution=)]
    2020-07-25 lovetcm

    #特异性皮炎#这个领域新药越来越多

    0

相关资讯

Gastroenterology:警惕JAK抑制剂治疗导致患者带状疱疹风险增加

接受JAK抑制剂治疗的免疫相关疾病患者带状疱疹风险显著增加

Incyte启动JAK抑制剂芦可替尼治疗COVID-19相关细胞因子风暴III期研究

4月17日,Incyte宣布启动一项代号为RUXCOVID的全球性、随机、双盲、安慰剂对照III期临床试验,计划在全球招募约400名患者,为期29天,主要评估Jakafi(芦可替尼)联合标准护理(So

瑞德西韦联合JAK抑制剂治疗COVID-19:ACTT 2试验即将开展

美国国家过敏和传染病研究所(NIAID)近日表示,正在为ACTT 2试验招募COVID-19患者。

综述:JAK抑制剂治疗银屑病

银屑病是一种常见的慢性炎症性疾病。炎症反应由T细胞驱动,并由多种细胞因子介导,如肿瘤坏死因子和白介素IL-17和IL-23。中度至重度银屑病采用生物制剂或常规小分子药物系统治疗。新型生物制剂非常有效且

礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果

礼来和Incyte宣布,其口服选择性JAK抑制剂baricitinib达到了BREEZE-AD5的主要研究终点。该研究为3期临床、随机安慰剂对照,用于评估Baricitinib治疗成人中重度特应性皮炎(AD)患者安全性和有效性的研究。主要终点指标定义为第16周时,湿疹面积和严重程度指数(EASI)与基线相比至少达到75%或更高比例。

JAK抑制剂baricitinib在III期特应性皮炎研究中显著改善皮肤炎症

礼来公司和Incyte公司近日报道,研究表明,在中度至重度特应性皮炎(AD)患者中评估Olumiant(baricitinib)的III期BREEZE-AD4试验达到了比基线至少改善75%(EASI75)的主要终点。